




ASO VISUAL ABSTRACT

## ASO Visual Abstract: Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma

Miriam Redegalli, PhD<sup>1,2</sup>, Marco Schiavo Lena, MD<sup>1,2</sup>, Maria Giulia Cangi, PhD<sup>1,2</sup>, Chanel Elisha Smart, PhD, MD<sup>1,2</sup>, Martina Mori, DMP<sup>4</sup>, Claudio Fiorino, MD<sup>4</sup>, Paolo Giorgio Arcidiacono, MD<sup>5</sup>, Gianpaolo Balzano, MD<sup>2,6</sup>, Massimo Falconi, MD<sup>2,6</sup>, Michele Reni, MD<sup>3</sup>, and Claudio Doglioni, MD<sup>1,2</sup>

<sup>1</sup>Pathology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy; <sup>2</sup>Vita-Salute San Raffaele University, Milan, Italy; <sup>3</sup>Department of Medical Oncology, Pancreas Translational and Clinical Research Centre, IRCCS San Raffaele Scientific Institute, Milan, Italy; <sup>4</sup>Medical Physics, San Raffaele Scientific Institute, Milano, Italy; <sup>5</sup>Pancreato-Biliary Endoscopy and Endosonography Division, Pancreas Translational and Clinical Research Centre, San Raffaele Scientific Institute, Vita Salute San Raffaele University, Milan, Italy; <sup>6</sup>Pancreatic Surgery Unit, Pancreas Translational and Clinical Research Centre, IRCCS San Raffaele Scientific Institute, Milan, Italy



Pancreatic ductal adenocarcinoma (PDAC) tumor morphology is significantly altered by neoadjuvant chemotherapy (NACT). Perineural invasion, lymph node ratio, and the stroma-to-neoplasia ratio are prognostic

factors for NACT-treated PDAC patients. The semi-quantitative pathologic prognostic index predicts patients' outcome after NACT followed by surgery (<http://doi.org/10.1245/s10434-022-11413-7>).

Miriam Redegalli and M. Schiavo Lena contributed equally to this manuscript and share first authorship.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Michelle Reni and C. Doglioni shared senior authorship.

© Society of Surgical Oncology 2022

Published Online: 21 March 2022

M. Reni, MD  
e-mail: reni.michele@hsr.it